FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:905-914 September 28, 2000 Number 13 Next

	Full Text PDF Editorial by Mayer, R. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer. Irinotecan prolongs survival in patients with colorectal cancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil, and leucovorin with bolus doses of fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. A third group of patients received irinotecan alone.

Methods Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bolus) weekly for four weeks every six weeks; fluorouracil (425 mg per square meter as an intravenous bolus) and leucovorin (20 mg per square meter as an intravenous bolus) daily for five consecutive days every four weeks; or irinotecan alone (125 mg per square meter intravenously) weekly for four weeks every six weeks. End points included progression-free survival and overall survival.

Results Of 683 patients, 231 were assigned to receive irinotecan, fluorouracil, and leucovorin; 226 to receive fluorouracil and leucovorin; and 226 to receive irinotecan alone. In an intention-to-treat analysis, as compared with treatment with fluorouracil and leucovorin, treatment with irinotecan, fluorouracil, and leucovorin resulted in significantly longer progression-free survival (median, 7.0 vs. 4.3 months; P=0.004), a higher rate of confirmed response (39 percent vs. 21 percent, P<0.001), and longer overall survival (median, 14.8 vs. 12.6 months; P=0.04). Results for irinotecan alone were similar to those for fluorouracil and leucovorin. Grade 3 (severe) diarrhea was more common during treatment with irinotecan, fluorouracil, and leucovorin than during treatment with fluorouracil and leucovorin, but the incidence of grade 4 (life-threatening) diarrhea was similar in the two groups (<8 percent). Grade 3 or 4 mucositis, grade 4 neutropenia, and neutropenic fever were less frequent during treatment with irinotecan, fluorouracil, and leucovorin. Adding irinotecan to the regimen of fluorouracil and leucovorin did not compromise the quality of life.

Conclusions Weekly treatment with irinotecan plus fluorouracil and leucovorin is superior to a widely used regimen of fluorouracil and leucovorin for metastatic colorectal cancer in terms of progression-free survival and overall survival.

Source Information

From Memorial Sloan-Kettering Cancer Center, New York (L.B.S.); U.S. Oncology, Dallas (J.V.C.); the Vanderbilt Cancer Center, Nashville (C.B.); UCLA Medical Center, Los Angeles (L.S.R.); Kaiser Permanente Medical Center, Vallejo, Calif. (L.F.); Princess Margaret Hospital, Toronto (M.J.M.); Ottawa Regional Cancer Center, Ottawa, Ont., Canada (J.A.M.); Newcastle Mater Misericordiae Hospital, Waratah, N.S.W., Australia (S.P.A.); and Pharmacia Corporation, Peapack, N.J. (P.K.L., N.P., G.L.E., L.L.M.).

Address reprint requests to Dr. Saltz at the Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

Full Text of this Article

Related Letters:

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Erlichman C., Goldberg R. M., O'Connell M. J., Vaiani M., Trippoli S., Messori A., Pestalozzi B. C., Pignon J.-P., Ducreux M., Saltz L. B., Miller L. L.
Extract | Full Text | PDF  
N Engl J Med 2001; 344:305-307, Jan 25, 2001. Correspondence

This article has been cited by other articles:

• Toffoli, G., Cecchin, E., Gasparini, G., D'Andrea, M., Azzarello, G., Basso, U., Mini, E., Pessa, S., De Mattia, E., Lo Re, G., Buonadonna, A., Nobili, S., De Paoli, P., Innocenti, F. (2010). Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. JCO 28: 866-871 [Abstract] [Full Text]  
• de Gramont, A., Haller, D. G., Sargent, D. J., Tabernero, J., Matheson, A., Schilsky, R. L. (2010). Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program. JCO 28: 527-530 [Full Text]  
• de Gramont, A., Hubbard, J., Shi, Q., O'Connell, M. J., Buyse, M., Benedetti, J., Bot, B., O'Callaghan, C., Yothers, G., Goldberg, R. M., Blanke, C. D., Benson, A., Deng, Q., Alberts, S. R., Andre, T., Wolmark, N., Grothey, A., Sargent, D. (2010). Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. JCO 28: 460-465 [Abstract] [Full Text]  
• van der Bol, J. M., Mathijssen, R. H.J., Creemers, G.-J. M., Planting, A. S.Th., Loos, W. J., Wiemer, E. A.C., Friberg, L. E., Verweij, J., Sparreboom, A., de Jong, F. A. (2010). A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan. Clin. Cancer Res. 16: 736-742 [Abstract] [Full Text]  
• Boku, N. (2010). Current Status and Problems in Development of Molecular Target Agents for Gastrointestinal Malignancy in Japan. Jpn J Clin Oncol 0: hyp171v1-hyp171 [Abstract] [Full Text]  
• Stein, A., Voigt, W., Jordan, K. (2010). Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Therapeutic Advances in Medical Oncology 2: 51-63 [Abstract]  
• Sobrero, A., Bruzzi, P. (2009). Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval. JCO 27: 5868-5873 [Full Text]  
• Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., Ducreux, M., Ychou, M., Bibeau, F., Bouche, O., Reid, J., Stone, S., Penault-Llorca, F. (2009). Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. JCO 27: 5924-5930 [Abstract] [Full Text]  
• Richman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., Quirke, P. (2009). KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial. JCO 27: 5931-5937 [Abstract] [Full Text]  
• Ychou, M., Hohenberger, W., Thezenas, S., Navarro, M., Maurel, J., Bokemeyer, C., Shacham-Shmueli, E., Rivera, F., Kwok-Keung Choi, C., Santoro, A. (2009). A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20: 1964-1970 [Abstract] [Full Text]  
• Cleary, J. M., Tanabe, K. T., Lauwers, G. Y., Zhu, A. X. (2009). Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. The Oncologist 14: 1095-1105 [Abstract] [Full Text]  
• Hendifar, A., Yang, D., Lenz, F., Lurje, G., Pohl, A., Lenz, C., Ning, Y., Zhang, W., Lenz, H.-J. (2009). Gender Disparities in Metastatic Colorectal Cancer Survival. Clin. Cancer Res. 15: 6391-6397 [Abstract] [Full Text]  
• Koizumi, W., Boku, N., Yamaguchi, K., Miyata, Y., Sawaki, A., Kato, T., Toh, Y., Hyodo, I., Nishina, T., Furuhata, T., Miyashita, K., Okada, Y. (2009). Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol 0: mdp371v1-mdp371 [Abstract] [Full Text]  
• Grothey, A., Sargent, D. J. (2009). Reply to F. Montagnani et al. JCO 27: e134-e135 [Full Text]  
• Goldberg, R. M., Sargent, D. J., Morton, R. F., Green, E., Sanoff, H. K., McLeod, H., Buckner, J. (2009). NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial. The Oncologist 14: 970-978 [Abstract] [Full Text]  
• Grothey, A. (2009). Review: Medical treatment of advanced colorectal cancer in 2009. Therapeutic Advances in Medical Oncology 1: 55-68 [Abstract]  
• van Hazel, G. A., Pavlakis, N., Goldstein, D., Olver, I. N., Tapner, M. J., Price, D., Bower, G. D., Briggs, G. M., Rossleigh, M. A., Taylor, D. J., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. JCO 27: 4089-4095 [Abstract] [Full Text]  
• Bessard, A., Sole, V., Bouchaud, G., Quemener, A., Jacques, Y. (2009). High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor {alpha} fusion protein, in metastatic melanoma and colorectal cancer. Molecular Cancer Therapeutics 8: 2736-2745 [Abstract] [Full Text]  
• Kozloff, M., Yood, M. U., Berlin, J., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., Sugrue, M. M., Grothey, A., for the investigators of the BRiTE study, (2009). Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. The Oncologist 14: 862-870 [Abstract] [Full Text]  
• Kopetz, S., Chang, G. J., Overman, M. J., Eng, C., Sargent, D. J., Larson, D. W., Grothey, A., Vauthey, J.-N., Nagorney, D. M., McWilliams, R. R. (2009). Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. JCO 27: 3677-3683 [Abstract] [Full Text]  
• KIM, J. C., ROH, S. A., CHO, D. H., KIM, T. W., YOON, S. N., KIM, C. W., YU, C. S., KIM, S. Y., KIM, Y. S. (2009). Chemoresponsiveness Associated with Canonical Molecular Changes in Colorectal Adenocarcinomas. Anticancer Res 29: 3115-3123 [Abstract] [Full Text]  
• Poultsides, G. A., Servais, E. L., Saltz, L. B., Patil, S., Kemeny, N. E., Guillem, J. G., Weiser, M., Temple, L. K.F., Wong, W. D., Paty, P. B. (2009). Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. JCO 27: 3379-3384 [Abstract] [Full Text]  
• Lim, H. J., Gill, S., Speers, C., Melosky, B., Barnett, J., Fitzgerald, C., O'Reilly, S., Kennecke, H. (2009). Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study. J Oncol Pract 5: 153-158 [Abstract] [Full Text]  
• Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M. A., Mitchell, E., Miller, M. C., Doyle, G. V., Tissing, H., Terstappen, L. W. M. M., Meropol, N. J. (2009). Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223-1229 [Abstract] [Full Text]  
• Kim, G. P., Sargent, D. J., Mahoney, M. R., Rowland, K. M. Jr, Philip, P. A., Mitchell, E., Mathews, A. P., Fitch, T. R., Goldberg, R. M., Alberts, S. R., Pitot, H. C. (2009). Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841. JCO 27: 2848-2854 [Abstract] [Full Text]  
• Onaitis, M. W., Petersen, R. P., Haney, J. C., Saltz, L., Park, B., Flores, R., Rizk, N., Bains, M. S., Dycoco, J., D'Amico, T. A., Harpole, D. H., Kemeny, N., Rusch, V. W., Downey, R. (2009). Prognostic Factors for Recurrence After Pulmonary Resection of Colorectal Cancer Metastases.. Ann. Thorac. Surg. 87: 1684-1688 [Abstract] [Full Text]  
• Inoue, Y., Toiyama, Y., Tanaka, K., Miki, C., Kusunoki, M. (2009). A Comprehensive Comparative Study on the Characteristics of Colorectal Cancer Chemotherapy. Jpn J Clin Oncol 39: 367-375 [Abstract] [Full Text]  
• Overman, M. J., Varadhachary, G. R., Kopetz, S., Adinin, R., Lin, E., Morris, J. S., Eng, C., Abbruzzese, J. L., Wolff, R. A. (2009). Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. JCO 27: 2598-2603 [Abstract] [Full Text]  
• Bidard, F.-C., Tournigand, C., Andre, T., Mabro, M., Figer, A., Cervantes, A., Lledo, G., Bengrine-Lefevre, L., Maindrault-Goebel, F., Louvet, C., de Gramont, A. (2009). Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol 20: 1042-1047 [Abstract] [Full Text]  
• TORIGOE, S., OGATA, Y., MATONO, K., SHIROUZU, K. (2009). Molecular Mechanisms of Sequence-dependent Antitumor Effects of SN-38 and 5-Fluorouracil Combination Therapy against Colon Cancer Cells. Anticancer Res 29: 2083-2089 [Abstract] [Full Text]  
• OGAWA, M., WATANABE, M., ETO, K., OMACHI, T., KOSUGE, M., HANYU, K., NOAKI, L., FUJITA, T., YANAGA, K. (2009). Clinicopathological Features of Perforated Colorectal Cancer. Anticancer Res 29: 1681-1684 [Abstract] [Full Text]  
• Fakih, M. G., Pendyala, L., Fetterly, G., Toth, K., Zwiebel, J. A., Espinoza-Delgado, I., Litwin, A., Rustum, Y. M., Ross, M. E., Holleran, J. L., Egorin, M. J. (2009). A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer. Clin. Cancer Res. 15: 3189-3195 [Abstract] [Full Text]  
• Sargent, D. J., Kohne, C. H., Sanoff, H. K., Bot, B. M., Seymour, M. T., de Gramont, A., Porschen, R., Saltz, L. B., Rougier, P., Tournigand, C., Douillard, J.-Y., Stephens, R. J., Grothey, A., Goldberg, R. M. (2009). Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. JCO 27: 1948-1955 [Abstract] [Full Text]  
• Adam, R., Wicherts, D. A., de Haas, R. J., Ciacio, O., Levi, F., Paule, B., Ducreux, M., Azoulay, D., Bismuth, H., Castaing, D. (2009). Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?. JCO 27: 1829-1835 [Abstract] [Full Text]  
• Van Cutsem, E., Kohne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pinter, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., Rougier, P. (2009). Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. NEJM 360: 1408-1417 [Abstract] [Full Text]  
• Ychou, M., Raoul, J.-L., Douillard, J.-Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., Viret, F., Becouarn, Y., Bouche, O., Gamelin, E., Ducreux, M., Conroy, T., Seitz, J.-F., Bedenne, L., Kramar, A. (2009). A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20: 674-680 [Abstract] [Full Text]  
• Chen, E., Jonker, D., Gauthier, I., MacLean, M., Wells, J., Powers, J., Seymour, L. (2009). Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer. Clin. Cancer Res. 15: 1481-1486 [Abstract] [Full Text]  
• Aranda, E., Valladares, M., Martinez-Villacampa, M., Benavides, M., Gomez, A., Massutti, B., Marcuello, E., Constenla, M., Camara, J. C., Carrato, A., Duenas, R., Reboredo, M., Navarro, M., Diaz-Rubio, E. (2009). Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol 20: 251-257 [Abstract] [Full Text]  
• BIR, A. S., FORA, A. A., LEVEA, C., FAKIH, M. G. (2009). Spontaneous Regression of Colorectal Cancer Metastatic to Retroperitoneal Lymph Nodes. Anticancer Res 29: 465-468 [Abstract] [Full Text]  
• Czock, D., Rasche, F. M., Boesler, B., Shipkova, M., Keller, F. (2009). Irinotecan in Cancer Patients with End-Stage Renal Failure. The Annals of Pharmacotherapy 43: 363-369 [Abstract] [Full Text]  
• Papamichael, D., Audisio, R., Horiot, J.-C., Glimelius, B., Sastre, J., Mitry, E., Van Cutsem, E., Gosney, M., Kohne, C.-H., Aapro, M. (2009). Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 20: 5-16 [Abstract] [Full Text]  
• KOLINSKY, K., ZHANG, Y.-E, DUGAN, U., HEIMBROOK, D., PACKMAN, K., HIGGINS, B. (2009). Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts. Anticancer Res 29: 91-98 [Abstract] [Full Text]  
• Zhu, A. X., Ready, N., Clark, J. W., Safran, H., Amato, A., Salem, N., Pace, S., He, X., Zvereva, N., Lynch, T. J., Ryan, D. P., Supko, J. G. (2009). Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors. Clin. Cancer Res. 15: 374-381 [Abstract] [Full Text]  
• Matsumura, Y. (2008). Polymeric Micellar Delivery Systems in Oncology. Jpn J Clin Oncol 38: 793-802 [Abstract] [Full Text]  
• Fisher, G. A., Kuo, T., Ramsey, M., Schwartz, E., Rouse, R. V., Cho, C. D., Halsey, J., Sikic, B. I. (2008). A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer. Clin. Cancer Res. 14: 7074-7079 [Abstract] [Full Text]  
• Alberts, S. R., Wagman, L. D. (2008). Chemotherapy for Colorectal Cancer Liver Metastases. The Oncologist 13: 1063-1073 [Abstract] [Full Text]  
• O'Neil, B. H., Goldberg, R. M. (2008). Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials. The Oncologist 13: 1074-1083 [Abstract] [Full Text]  
• Ward, J., Guthrie, J. A., Sheridan, M. B., Boyes, S., Smith, J. T., Wilson, D., Wyatt, J. I., Treanor, D., Robinson, P. J. (2008). Sinusoidal Obstructive Syndrome Diagnosed With Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging in Patients With Chemotherapy-Treated Colorectal Liver Metastases. JCO 26: 4304-4310 [Abstract] [Full Text]  
• Meulenbeld, H. J., van Steenbergen, L. N., Janssen-Heijnen, M. L. G., Lemmens, V. E. P. P., Creemers, G. J. (2008). Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol 19: 1600-1604 [Abstract] [Full Text]  
• Kabbinavar, F. F., Wallace, J. F., Holmgren, E., Yi, J., Cella, D., Yost, K. J., Hurwitz, H. I. (2008). Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer. The Oncologist 13: 1021-1029 [Abstract] [Full Text]  
• Kaufman, H. L., Lenz, H.-J., Marshall, J., Singh, D., Garett, C., Cripps, C., Moore, M., von Mehren, M., Dalfen, R., Heim, W. J., Conry, R. M., Urba, W. J., Benson, A. B. III, Yu, M., Caterini, J., Kim-Schulze, S., DeBenedette, M., Salha, D., Vogel, T., Elias, I., Berinstein, N. L. (2008). Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer. Clin. Cancer Res. 14: 4843-4849 [Abstract] [Full Text]  
• McKibbin, T., Frei, C. R., Greene, R. E., Kwan, P., Simon, J., Koeller, J. M. (2008). Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting. The Oncologist 13: 876-885 [Abstract] [Full Text]  
• Carethers, J. M. (2008). Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor. Therapeutic Advances in Gastroenterology 1: 33-42 [Abstract]  
• Qvortrup, C., Yilmaz, M., Ogreid, D., Berglund, A., Balteskard, L., Ploen, J., Fokstuen, T., Starkhammar, H., Sorbye, H., Tveit, K., Pfeiffer, P. (2008). Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Ann Oncol 19: 1154-1159 [Abstract] [Full Text]  
• van Iersel, L. B. J., Gelderblom, H., Vahrmeijer, A. L., van Persijn van Meerten, E. L., Tijl, F. G. J., Putter, H., Hartgrink, H. H., Kuppen, P. J. K., Nortier, J. W. R., Tollenaar, R. A. E. M., van de Velde, C. J. H. (2008). Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 19: 1127-1134 [Abstract] [Full Text]  
• Schwartz, R. N. (2008). Management of early and advanced colorectal cancer: Therapeutic issues. Am J Health Syst Pharm 65: S8-S14 [Abstract] [Full Text]  
• Hecht, J. R. (2008). Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice. Am J Health Syst Pharm 65: S15-S21 [Abstract] [Full Text]  
• O'Connell, M. J., Campbell, M. E., Goldberg, R. M., Grothey, A., Seitz, J.-F., Benedetti, J. K., Andre, T., Haller, D. G., Sargent, D. J. (2008). Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set. JCO 26: 2336-2341 [Abstract] [Full Text]  
• Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., Lenz, H.-J., Borg, C., Middleton, G., Kroning, H., Luppi, G., Kisker, O., Zubel, A., Langer, C., Kopit, J., Burris, H. A. III (2008). EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. JCO 26: 2311-2319 [Abstract] [Full Text]  
• Glimelius, B., Sorbye, H., Balteskard, L., Bystrom, P., Pfeiffer, P., Tveit, K., Heikkila, R., Keldsen, N., Albertsson, M., Starkhammar, H., Garmo, H., Berglund, A. (2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 19: 909-914 [Abstract] [Full Text]  
• Adam, R., Wicherts, D. A., de Haas, R. J., Aloia, T., Levi, F., Paule, B., Guettier, C., Kunstlinger, F., Delvart, V., Azoulay, D., Castaing, D. (2008). Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?. JCO 26: 1635-1641 [Abstract] [Full Text]  
• Xue, H., Sawyer, M. B., Field, C. J., Dieleman, L. A., Murray, D., Baracos, V. E. (2008). Bolus Oral Glutamine Protects Rats against CPT-11-Induced Diarrhea and Differentially Activates Cytoprotective Mechanisms in Host Intestine but Not Tumor. J. Nutr. 138: 740-746 [Abstract] [Full Text]  
• Kohne, C.-H., Folprecht, G., Goldberg, R. M., Mitry, E., Rougier, P. (2008). Chemotherapy in Elderly Patients with Colorectal Cancer. The Oncologist 13: 390-402 [Abstract] [Full Text]  
• Folprecht, G., Seymour, M. T., Saltz, L., Douillard, J.-Y., Hecker, H., Stephens, R. J., Maughan, T. S., Van Cutsem, E., Rougier, P., Mitry, E., Schubert, U., Kohne, C.-H. (2008). Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. JCO 26: 1443-1451 [Abstract] [Full Text]  
• Sapra, P., Zhao, H., Mehlig, M., Malaby, J., Kraft, P., Longley, C., Greenberger, L. M., Horak, I. D. (2008). Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11-Refractory Model. Clin. Cancer Res. 14: 1888-1896 [Abstract] [Full Text]  
• Zalcberg, J. R., Rosen, L. S., Abdi, E., Davis, I. D., Gutheil, J., Schnell, F. M., Cesano, A., Gayko, U., Chen, M.-G., Clarke, S. (2008). Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer. JCO 26: 1386-1387 [Full Text]  
• Ramsay, E. C., Anantha, M., Zastre, J., Meijs, M., Zonderhuis, J., Strutt, D., Webb, M. S., Waterhouse, D., Bally, M. B. (2008). Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors. Clin. Cancer Res. 14: 1208-1217 [Abstract] [Full Text]  
• Van Cutsem, E., Verslype, C., Beale, P., Clarke, S., Bugat, R., Rakhit, A., Fettner, S. H., Brennscheidt, U., Feyereislova, A., Delord, J.-P (2008). A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol 19: 332-339 [Abstract] [Full Text]  
• Lievre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouche, O., Landi, B., Louvet, C., Andre, T., Bibeau, F., Diebold, M.-D., Rougier, P., Ducreux, M., Tomasic, G., Emile, J.-F., Penault-Llorca, F., Laurent-Puig, P. (2008). KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. JCO 26: 374-379 [Abstract] [Full Text]  
• Grothey, A., Hedrick, E. E., Mass, R. D., Sarkar, S., Suzuki, S., Ramanathan, R. K., Hurwitz, H. I., Goldberg, R. M., Sargent, D. J. (2008). Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. JCO 26: 183-189 [Abstract] [Full Text]  
• Pawlik, T. M., Schulick, R. D., Choti, M. A. (2008). Expanding Criteria for Resectability of Colorectal Liver Metastases. The Oncologist 13: 51-64 [Abstract] [Full Text]  
• Becouarn, Y., Senesse, P., Thezenas, S., Boucher, E., Adenis, A., Cany, L., Jacob, J. H., Cvitkovic, F., Montoto-Grillot, C., Ychou, M. (2007). A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Federation Nationale des Centres de Lutte Contre le Cancer. Ann Oncol 18: 2000-2005 [Abstract] [Full Text]  
• Tang, M. J., Tai, I. T. (2007). A Novel Interaction between Procaspase 8 and SPARC Enhances Apoptosis and Potentiates Chemotherapy Sensitivity in Colorectal Cancers. J. Biol. Chem. 282: 34457-34467 [Abstract] [Full Text]  
• Buyse, M., Burzykowski, T., Carroll, K., Michiels, S., Sargent, D. J., Miller, L. L., Elfring, G. L., Pignon, J.-P., Piedbois, P. (2007). Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. JCO 25: 5218-5224 [Abstract] [Full Text]  
• Tabernero, J., Van Cutsem, E., Diaz-Rubio, E., Cervantes, A., Humblet, Y., Andre, T., Van Laethem, J.-L., Soulie, P., Casado, E., Verslype, C., Valera, J. S., Tortora, G., Ciardiello, F., Kisker, O., de Gramont, A. (2007). Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. JCO 25: 5225-5232 [Abstract] [Full Text]  
• Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., Moore, M. J. (2007). Cetuximab for the Treatment of Colorectal Cancer. NEJM 357: 2040-2048 [Abstract] [Full Text]  
• Benson, A. B. III (2007). New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease. Clin. Cancer Res. 13: 6913s-6920s [Abstract] [Full Text]  
• Kornprat, P., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Blumgart, L. H., D'Angelica, M. (2007). Role of Intraoperative Thermoablation Combined With Resection in the Treatment of Hepatic Metastasis From Colorectal Cancer. Arch Surg 142: 1087-1092 [Abstract] [Full Text]  
• Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., Schulz, J., Richards, D., Soufi-Mahjoubi, R., Wang, B., Barrueco, J. (2007). Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study. JCO 25: 4779-4786 [Abstract] [Full Text]  
• Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gonen, M., Kemeny, N., Brennan, M. F., Blumgart, L. H., D'Angelica, M. (2007). Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure. JCO 25: 4575-4580 [Abstract] [Full Text]  
• Tang, P. A., Bentzen, S. M., Chen, E. X., Siu, L. L. (2007). Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy. JCO 25: 4562-4568 [Abstract] [Full Text]  
• Sorbye, H., Kohne, C.-H., Sargent, D. J., Glimelius, B. (2007). Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 18: 1666-1672 [Abstract] [Full Text]  
• Yoshino, T., Boku, N., Onozawa, Y., Hironaka, S., Fukutomi, A., Yamaguchi, Y., Hasuike, N., Yamazaki, K., Machida, N., Ono, H. (2007). Efficacy and Safety of an Irinotecan plus Bolus 5-Fluorouracil and L-Leucovorin Regimen for Metastatic Colorectal Cancer in Japanese Patients: Experience in a Single Institution in Japan. Jpn J Clin Oncol 37: 686-691 [Abstract] [Full Text]  
• Zhang, W., Press, O. A., Haiman, C. A., Yang, D. Y., Gordon, M. A., Fazzone, W., El-khoueiry, A., Iqbal, S., Sherrod, A. E., Lurje, G., Lenz, H.-J. (2007). Association of Methylenetetrahydrofolate Reductase Gene Polymorphisms and Sex-Specific Survival in Patients With Metastatic Colon Cancer. JCO 25: 3726-3731 [Abstract] [Full Text]